Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

Here’s what we learned about the efficacy of antibody drug conjugates targeting predictive biomarkers in second-line non-small cell lung cancer.

ReachMD Healthcare Image
Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free